Cidara Therapeutics
Trial Pipeline
A Trial to Evaluate the Effect of CD388 on the Immunogenicity of Fluzone® HD Vaccine
NCT07300085
A Study to Evaluate the Safety, Pharmacokinetics, and Occurrence of Anti-Drug Antibodies Following Annual Doses of CD388
NCT07225959
A Study to Evaluate the Safety and Efficacy of CD388 for Prevention of Influenza
NCT07159763
Study of CD388 for the Prevention of Influenza in Subjects Not at Risk for Influenza Complications
NCT06609460
CD101 Compared to Caspofungin Followed by Oral Step Down in Subjects With Candidemia and/or Invasive Candidiasis-Bridging Extension
NCT02734862
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 3 |
| Phase 3 | 1 |
Therapeutic Areas
What the Pipeline for Cidara Therapeutics Shows
According to the ClinicalTrials.gov registry, Cidara Therapeutics is linked to 5 US clinical trials across every stage of research activity. Of those, 1 studies are currently recruiting — about 20% of the sponsor's indexed portfolio — and 2 are already marked complete, representing roughly 40% of the total. Recruiting share is one of the more practical signals here: it reflects how much of a sponsor's research is presently open to new participants, while the completed share indicates the depth of finished work that has already contributed registry results. Both counts come directly from the public ClinicalTrials.gov dataset and are refreshed on the registry side; this page mirrors the latest data pull without altering it.
The phase mix for Cidara Therapeutics reports 1 late-stage studies (Phase 3 and Phase 4 combined) and 4 earlier-phase studies (Phase 1 and Phase 2). A portfolio weighted toward Phase 3 usually reflects an organization advancing candidates toward regulatory review, where the research centers on comparative efficacy and broader safety across larger populations. A heavier Phase 1 and Phase 2 tilt generally indicates exploratory work — safety, dosing, and early signal detection — and is common among research-forward sponsors that seed many early programs. Phase 4 entries, when present, track interventions already in real-world use and typically focus on long-term safety, effectiveness across subgroups, or formulation comparisons.
The top therapeutic focus area indexed for Cidara Therapeutics is Influenza with 2 linked trials, and 6 other condition areas appear in the top list above. That distribution is a quick read of where the organization concentrates its research attention; it does not imply product availability, market share, or any clinical endorsement. All numbers on this page come from ClinicalTrials.gov maintained by the National Library of Medicine, and counts can shift as new studies are registered or existing ones update their status. This information is provided for reference and educational purposes only, not as medical, investment, or regulatory advice — verify current details directly with ClinicalTrials.gov before relying on any figure here.
Read our methodology — how this data is sourced, computed, and verified.